Cerexa Inc. competitors

Zippia score 3.8

Competitor Summary. See how Cerexa Inc. compares to its main competitors:

Optimer Pharmaceuticals has the most employees (281).

Work at Cerexa Inc.?

Share your experience

Cerexa Inc. vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Cerexa Inc.	2005	3.8	Alameda, CA	1	$1.3M	29
Nabriva Therapeutics	2006	4.1	San Diego, CA	1	$12.0M	175
Spero Therapeutics	2013	4.3	Cambridge, MA	2	$48.0M	41
triusrx.com	2004	4.2	San Diego, CA	1	$27.2M	50
Geom Therapeutics	2015	3.3	San Francisco, CA	1	$120,000	6
Vicuron Pharmaceuticals	-	3.7	King of Prussia, PA	1	$21.0M	200
Optimer Pharmaceuticals	1998	4.6	San Diego, CA	1	$144.0M	281
Facet Biotech	2008	4.2	Redwood City, CA	1	-	75

Rate how well Cerexa Inc. differentiates itself from its competitors.

Cerexa Inc. salaries vs competitors

Compare Cerexa Inc. salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Cerexa Inc.	$46,963	$22.58	-

Compare Cerexa Inc. job title salaries vs competitors

Company	Highest salary	Hourly salary
Cerexa Inc.	$32,708	$15.72
Optimer Pharmaceuticals	$36,809	$17.70
Nabriva Therapeutics	$34,862	$16.76
Spero Therapeutics	$34,148	$16.42
triusrx.com	$33,868	$16.28
Facet Biotech	$32,509	$15.63
Vicuron Pharmaceuticals	$32,126	$15.45
Geom Therapeutics	$32,028	$15.40

Do you work at Cerexa Inc.?

Is Cerexa Inc. able to compete effectively with similar companies?

Cerexa Inc. jobs

Cerexa Inc. and similar companies CEOs

CEOBio

Daryl Mims

Optimer Pharmaceuticals

Daryl Mims is a Global Business Partner, CEO/CIO and many VPs at OPTIMER PHARMACEUTICALS INC and is based in Sewaren, New Jersey. He has experience at National Basketball Association (NBA) and has worked as Helpdesk Analyst at Medco Health Solutions, Inc. and Desktop Support / Consultant at Verizon Corporate HQ. Daryl attended Bayonne High School between 1991 and 1995.

Ankit Mahadevia M.d

Spero Therapeutics

CEO of Spero Therapeutics, a public, clinical stage company developing a pipeline of therapeutics treating large unmet needs in infectious disease. Co-founder of nine biotech startups developing novel platforms and therapies, including Spero Therapeutics (Nasdaq:SPRO), Synlogic (Nasdaq: SYBX), and Arteaus Therapeutics (Acquired by Eli Lilly, Emgality FDA approved by Eli Lilly). Advisor at Atlas Venture, an early stage life sciences and technology venture capital firm. Some more on my perspective at http://lifescivc.com/2014/04/building-great-startup-teams-in-biotech-a-three-hour-tour, http://lifescivc.com/2014/07/growing-beyond-the-startup-phase-lessons-learned, and at https://timmermanreport.com/2018/08/zigging-when-others-zag-speros-ankit-mahadevia-on-the-antibiotic-opportunity.

Theodore R. Schroeder

Nabriva Therapeutics